MARKET NEWS

Aravive Announces Phase 3 Trial Design for AVB-500 in Platinum Resistant Ovarian Cancer
uniQure Announces Positive Top-Line Data From the HOPE-B Pivotal Trial of  Gene Therapy 
PMV Pharma Doses First Patient in Phase 1/2 Study of First-in-Class Precision Oncology Therapy
Ocuphire Pharma Announces First Patient Enrolled in Phase 3 Clinical Trial
Catalent Signs Commercial Supply Agreement With Blueprint Medicines
AB201 Development as a Potential Treatment for COVID-19 Receives US FDA Fast-Track Designation

  FEATURED EDITORIAL

  COMPANY PROFILE

Celanese works closely with you as a strategic partner to create innovative controlled-release dosage forms for biologics and small molecules to meet the goals of patient-centric therapies, improved medicine and better healthcare economics. Our scientists and engineers are there from concept to commercialization, providing development services, material supply aligned with GMP principles and regulatory support. Our objective is to help our customers reduce time and risk in research and development, so their drug achieves a higher chance of success. Our VitalDose® Ethylene-Vinyl Acetate (EVA) copolymer drug-delivery platform is an enabling technology for drug-eluting implants, inserts and transdermal films. The platform is flexible and customizable to address a variety of formulation challenges when it comes to tailoring the release rate of your drug. Click here for more.

  EXCLUSIVE ONLINE CONTENT

BioNTech & InstaDeep Announce Strategic Collaboration & Form AI Innovation Lab to Develop Novel Immunotherapies

BioNTech & InstaDeep Announce Strategic Collaboration & Form AI Innovation Lab to Develop Novel Immunotherapies

BioNTech SE and InstaDeep Ltd recently announced a multi-year strategic collaboration aimed at applying the latest advances in artificial intelligence (AI) and machine learning (ML) technology to develop….

Foster Corporation Enters Marketing Partnership With Aran Biomedical

Foster Corporation Enters Marketing Partnership With Aran Biomedical

Foster Corporation recently announce a new business relationship with Aran Biomedical, a global leader in biomaterial product solutions for implantable medical devices…..

Recipharm Announces Signature of Letter of Intent for Aseptic Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine Candidate

Recipharm Announces Signature of Letter of Intent for Aseptic Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine Candidate

Recipharm, a leading contract development and manufacturing organization (CDMO), recently announced that it has signed a letter of intent with Moderna, a US-based biotech company, to formulate, fill, and….

Benefits of Small-Scale Drug Development

Benefits of Small-Scale Drug Development

Kieran Coffey, Technical Lead at Pfizer CentreOne’s Newbridge facility, discusses the benefits of small-scale processing for process development of tablet products.

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

December 9 – Drug Delivery
December 16 – Parenteral Contract Manufacturing